Allogeneic HSCT for autoimmune disease: a shared decision

Nature Reviews Rheumatology, Published online: 17 September 2019; doi:10.1038/s41584-019-0306-7Autologous haematopoietic stem cell transplantation (HSCT) can be an effective treatment for refractory autoimmune diseases. With reports of the use of allogeneic HSCT emerging, how do these two very different types of stem cell transplantation compare and is allogeneic HSCT advisable?
Source: Nature Reviews Rheumatology - Category: Rheumatology Authors: Source Type: research

Related Links:

Purpose of review Autologous hematopoietic stem cell transplantation (HSCT) is a promising therapeutic modality for severe autoimmune diseases. In this review, we will outline the immunological mechanisms and the clinical evidence and experiences for therapeutic HSCT in autoimmune diseases, with particular focus on systemic sclerosis and multiple sclerosis. Recent findings Approximately 3000 patients with autoimmune diseases worldwide have been treated with HSCT. HSCT in systemic sclerosis has been shown in three randomized controlled trials to be associated with significant long-term event-free survival despite some ...
Source: Current Opinion in Hematology - Category: Hematology Tags: HEMATOPOIETIC STEM CELL TRANSPLANTATION: Edited by David Rizzieri Source Type: research
AbstractDendritic cell-based immunotherapy, which uses a patient's own immune cells, can be used for cancer treatment and allergy control, such as autoimmune disease and rejection associated with transplantation. However, these treatments create a burden on patients due to repeated blood collection. We used cell biological analysis of monocytes with few mutations obtained from minimal blood collection for genome recombination. Next, we established human peripheral blood monocyte-derived induced pluripotent stem cells (iPSCs) using a commercial vector and standard culture method. We found that when established iPSCs were in...
Source: Medical Molecular Morphology - Category: Molecular Biology Source Type: research
Bone Marrow Transplantation, Published online: 26 September 2019; doi:10.1038/s41409-019-0684-0Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)
Source: Bone Marrow Transplantation - Category: Hematology Authors: Source Type: research
Bone Marrow Transplantation, Published online: 25 September 2019; doi:10.1038/s41409-019-0680-4Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT)
Source: Bone Marrow Transplantation - Category: Hematology Authors: Source Type: research
The term hemolytic uremic syndrome (HUS) encompasses 3 different entities: typical HUS caused by a shiga toxin –producing Escherichia coli, primary atypical HUS (aHUS) resulting from the dysregulation of the complement alternative pathway, and secondary HUS caused by a variety of etiologies whose common characteristic is to induce diffuse endothelial damage leading to thrombotic microangiopathy (TMA). As s hown in Supplementary Table S1, the most common causes of secondary HUS are drugs, infections, autoimmune diseases, malignancies, and hematopoietic stem cell transplantation.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Controversies in Nephrology Source Type: research
Autoimmune hemolytic anemia (AIHA) occurs more frequently than other autoimmune hematological diseases (AHDs) after allogeneic hematopoietic stem cell transplantation. Haploidentical donors and chronic graft vs host disease are risk factors for AIHA and corticosteroids combined with cyclosporine A are superior to corticosteroids as initial treatment for AIHA. AIHA does not contribute to increase treatment ‐related mortality and could reduce the malignant diseases relapse and increase disease‐free survival. AbstractTo investigate the incidence and risk factors as well as prognosis of autoimmune hemolytic anemia (AIHA) f...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Allogeneic hematopoietic stem cell transplantation is a potential treatment for a wide range of conditions including cancer immunodeficiency and autoimmune disease 1-3. Historically, the primary sources for these cells have been bone marrow and peripheral blood, and in the last 10 years umbilical cord blood (UCB) has become recognised as an important additional source. UCB can be cryopreserved immediately post-partum and stored at ultra-low temperatures until required, with more than 700,000 cord blood units being stored this way worldwide 1, 4.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Publication date: Available online 2 September 2019Source: Life SciencesAuthor(s): Sahar Rostami Mansoor, Ebrahim Zabihi, Maryam Ghasemi-KasmanAbstractMultiple sclerosis (MS) is a chronic autoimmune inflammatory disease of the central nervous system (CNS). In attempt to identify an appropriate treatment for improving the neurological symptoms and remyelination process, autologous and allogenic transplantation of mesenchymal stem cells (MSCs) have been introduced as an effective therapeutic strategy in MS. MSCs are a heterogeneous subset of pluripotent non-hematopoietic stromal cells that are isolated from bone marrow, adip...
Source: Life Sciences - Category: Biology Source Type: research
Abstract Systemic sclerosis is a complex autoimmune connective tissue disease which carries a significant burden of disease-related morbidity including potentially life-threatening complications. Systemic sclerosis can affect all the major organs and therefore, although the disease is uncommon, many hospital-based specialists are involved in patient care. Vascular disease (e.g. Raynaud's phenomenon) is an almost universal symptom in patients with systemic sclerosis and is often the earliest manifestation of the disease. Systemic sclerosis not uncommonly can overlap with other rheumatological conditions (e.g. rheum...
Source: British Journal of Hospital Medicine - Category: Internal Medicine Authors: Tags: Br J Hosp Med (Lond) Source Type: research
AbstractPurpose of ReviewType 1 diabetes (T1D) is an autoimmune disease in which the immune cells selectively destroy the pancreatic beta ( β) cells and results in the deficiency of insulin production. The optimal treatment strategy for T1D should be preventing of β-cell destruction in the pancreas. The purpose of this review is to discuss the immunological therapeutic mechanisms that will help to understand the development and contro l of β-cell destruction. The review also presents a novel method for development of autoantigen (Ag)-specific regulatory T cells (Tregs) for T1D immunotherapy.Recent FindingsPa...
Source: Current Diabetes Reports - Category: Endocrinology Source Type: research
More News: Autoimmune Disease | Rheumatology | Stem Cell Therapy | Stem Cells | Transplants